Relmada Q3 2023 Earnings Report
Key Takeaways
Relmada Therapeutics announced its third quarter financial results and provided a corporate update, highlighting the progress of its Phase 3 clinical development plan for REL-1017 and upcoming milestones.
Advanced Phase 3 clinical development plan for REL-1017 as an adjunctive treatment for major depressive disorder (MDD).
Enrollment in Reliance II (study 302) is progressing as planned and it remains on track to be completed in the first half of 2024.
Initial patients have been enrolled into Relight, the new Phase 3 study (study 304), and continue to anticipate the completion of this trial in the second half of next year.
Presented new compelling preclinical data demonstrating the beneficial effect of non-psychedelic/low dose psilocybin on multiple metabolic parameters in a rodent model of metabolic dysfunction-associated steatotic liver disease (MASLD).
Relmada
Relmada
Forward Guidance
Relmada Therapeutics intends to commence a single-ascending dose Phase 1 trial in obese patients with steatotic liver disease in early 2024 to define the pharmacokinetic, safety, and tolerability profile of our modified-release psilocybin formulation in this population, followed by a Phase 2a trial in the same patient population to establish clinical proof-of-concept.